Regeneron (NASDAQ: REGN) reported Q4 EPS of $3.04, $0.01 better than the analyst estimate of $3.03. Revenue for the quarter came in at $1.23 billion versus the consensus estimate of $1.3 billion.

"The hard work of our scientists over the last decades has brought Regeneron to the next phase of our evolution - this year we anticipate launching two additional important therapies, significantly expanding our impact for patients with serious diseases and our company\'s growth potential," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "In March, we look forward to the potential U.S. approval of Dupixent, our innovative and breakthrough IL4/13 blocking antibody, in adults with atopic dermatitis. We believe Dupixent may have the potential to help additional patients with serious allergic diseases, with pivotal Phase 3 data in adult asthma patients expected later this year. We are also studying Dupixent in patients with nasal polyps and pediatric patients with asthma or atopic dermatitis."

FY 2017 GUIDANCE

EYLEA U.S. net product sales	Single digit percentage growth over 2016
Sanofi reimbursement of Regeneron commercialization-related expenses	$400 million - $450 million
Non-GAAP unreimbursed R&D(2) (4)	$950 million - $1.025 billion
Non-GAAP SG&A(2) (4)	$1.175 billion - $1.250 billion
Effective tax rate	Capital expenditures	$375 million - $450 million

For earnings history and earnings-related data on Regeneron (REGN) click here.